Sphingolipids in Asthma Pathogenesis

Sphingomyelin in Asthma Pathogenesis

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06539221

Enrollment

200

Registered

2024-08-06

Start date

2024-09-01

Completion date

2026-09-01

Last updated

2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, Th17, T-cell senescence, Sphingolipids, ceramide

Brief summary

The study aims to investigate the relationship between the small molecule metabolite sphingolipids and asthma clinical features and explore its involvement in asthma pathogenesis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* 1\. clinical diagnosis of asthma

Exclusion criteria

* 1\. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.

Design outcomes

Primary

Measure	Time frame	Description
lipidomics	Day 1	collect blood for lipidomic analysis and in vitro assays

Countries

China

Contacts

Primary ContactChun Chang

changc@bjmu.edu.cn15810075362

Outcome results